Annual SG&A
$149.18 M
+$5.66 M+3.94%
31 December 2023
Summary:
Halozyme Therapeutics annual selling, general & administrative expenses is currently $149.18 million, with the most recent change of +$5.66 million (+3.94%) on 31 December 2023. During the last 3 years, it has risen by +$103.45 million (+226.18%). HALO annual SG&A is now at all-time high.HALO Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$41.24 M
+$5.53 M+15.49%
30 September 2024
Summary:
Halozyme Therapeutics quarterly selling, general & administrative expenses is currently $41.24 million, with the most recent change of +$5.53 million (+15.49%) on 30 September 2024. Over the past year, it has increased by +$5.97 million (+16.93%). HALO quarterly SG&A is now -28.25% below its all-time high of $57.48 million, reached on 30 June 2022.HALO Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
$916.17 M
+$175.34 M+23.67%
30 September 2024
Summary:
Halozyme Therapeutics TTM selling, general & administrative expenses is currently $916.17 million, with the most recent change of +$175.34 million (+23.67%) on 30 September 2024. Over the past year, it has increased by +$766.85 million (+513.55%). HALO TTM SG&A is now at all-time high.HALO TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +3.9% | +16.9% | +513.5% |
| 3 y3 years | +226.2% | +213.2% | +1850.3% |
| 5 y5 years | +145.3% | +129.4% | +1184.0% |
HALO Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +226.2% | -28.3% | +213.2% | at high | +166.6% |
| 5 y | 5 years | at high | +226.2% | -28.3% | +295.5% | at high | +138.7% |
| alltime | all time | at high | >+9999.0% | -28.3% | >+9999.0% | at high | +136.7% |
Halozyme Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $41.24 M(+15.5%) | $149.69 M(+4.2%) |
| June 2024 | - | $35.71 M(+1.6%) | $143.72 M(-2.2%) |
| Mar 2024 | - | $35.13 M(-6.6%) | $146.96 M(-1.5%) |
| Dec 2023 | $149.18 M(+3.9%) | $37.61 M(+6.6%) | $149.18 M(-0.1%) |
| Sept 2023 | - | $35.27 M(-9.4%) | $149.32 M(+0.5%) |
| June 2023 | - | $38.95 M(+4.3%) | $148.52 M(-11.1%) |
| Mar 2023 | - | $37.36 M(-1.0%) | $167.05 M(+16.4%) |
| Dec 2022 | $143.53 M(+185.2%) | $37.75 M(+9.5%) | $143.53 M(+20.1%) |
| Sept 2022 | - | $34.47 M(-40.0%) | $119.55 M(+21.7%) |
| June 2022 | - | $57.48 M(+315.5%) | $98.25 M(+85.0%) |
| Mar 2022 | - | $13.83 M(+0.4%) | $53.10 M(+5.5%) |
| Dec 2021 | $50.32 M(+10.0%) | $13.77 M(+4.6%) | $50.32 M(+7.1%) |
| Sept 2021 | - | $13.17 M(+6.9%) | $46.98 M(+3.2%) |
| June 2021 | - | $12.32 M(+11.4%) | $45.51 M(+3.0%) |
| Mar 2021 | - | $11.06 M(+6.1%) | $44.16 M(-3.4%) |
| Dec 2020 | $45.74 M(-40.8%) | $10.43 M(-10.9%) | $45.74 M(-22.8%) |
| Sept 2020 | - | $11.70 M(+6.6%) | $59.24 M(-9.6%) |
| June 2020 | - | $10.97 M(-13.1%) | $65.52 M(-8.9%) |
| Mar 2020 | - | $12.63 M(-47.2%) | $71.88 M(-7.0%) |
| Dec 2019 | $77.25 M(+27.1%) | $23.93 M(+33.1%) | $77.25 M(+8.3%) |
| Sept 2019 | - | $17.98 M(+3.7%) | $71.35 M(+4.6%) |
| June 2019 | - | $17.34 M(-3.7%) | $68.24 M(+4.6%) |
| Mar 2019 | - | $18.01 M(-0.1%) | $65.25 M(+7.3%) |
| Dec 2018 | $60.80 M(+13.0%) | $18.03 M(+21.3%) | $60.80 M(+5.7%) |
| Sept 2018 | - | $14.86 M(+3.6%) | $57.54 M(+2.7%) |
| June 2018 | - | $14.35 M(+5.9%) | $56.01 M(+2.3%) |
| Mar 2018 | - | $13.56 M(-8.2%) | $54.76 M(+1.7%) |
| Dec 2017 | $53.82 M(+17.4%) | $14.77 M(+10.8%) | $53.82 M(+5.0%) |
| Sept 2017 | - | $13.33 M(+1.7%) | $51.27 M(+3.5%) |
| June 2017 | - | $13.10 M(+3.9%) | $49.54 M(+3.9%) |
| Mar 2017 | - | $12.62 M(+3.2%) | $47.66 M(+3.9%) |
| Dec 2016 | $45.85 M(+14.6%) | $12.23 M(+5.4%) | $45.85 M(+3.7%) |
| Sept 2016 | - | $11.60 M(+3.4%) | $44.22 M(+3.2%) |
| June 2016 | - | $11.22 M(+3.8%) | $42.84 M(+3.4%) |
| Mar 2016 | - | $10.81 M(+2.0%) | $41.44 M(+3.5%) |
| Dec 2015 | $40.03 M(+11.4%) | $10.59 M(+3.5%) | $40.03 M(+5.9%) |
| Sept 2015 | - | $10.23 M(+4.2%) | $37.79 M(+4.5%) |
| June 2015 | - | $9.81 M(+4.4%) | $36.15 M(+3.0%) |
| Mar 2015 | - | $9.40 M(+12.5%) | $35.09 M(-2.4%) |
| Dec 2014 | $35.94 M(+11.1%) | $8.35 M(-2.7%) | $35.94 M(-2.7%) |
| Sept 2014 | - | $8.59 M(-1.9%) | $36.95 M(+1.2%) |
| June 2014 | - | $8.75 M(-14.6%) | $36.49 M(+4.1%) |
| Mar 2014 | - | $10.25 M(+9.6%) | $35.04 M(+8.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2013 | $32.35 M(+30.4%) | $9.36 M(+15.0%) | $32.35 M(+7.9%) |
| Sept 2013 | - | $8.13 M(+11.4%) | $29.97 M(+9.1%) |
| June 2013 | - | $7.30 M(-3.4%) | $27.47 M(+6.7%) |
| Mar 2013 | - | $7.56 M(+8.3%) | $25.75 M(+3.8%) |
| Dec 2012 | $24.81 M(+37.1%) | $6.98 M(+23.9%) | $24.81 M(+4.7%) |
| Sept 2012 | - | $5.63 M(+1.0%) | $23.70 M(+6.1%) |
| June 2012 | - | $5.58 M(-15.7%) | $22.33 M(+4.8%) |
| Mar 2012 | - | $6.62 M(+12.8%) | $21.32 M(+17.7%) |
| Dec 2011 | $18.10 M(+19.7%) | $5.87 M(+37.6%) | $18.10 M(+7.3%) |
| Sept 2011 | - | $4.26 M(-6.7%) | $16.87 M(+5.6%) |
| June 2011 | - | $4.57 M(+34.1%) | $15.98 M(+8.2%) |
| Mar 2011 | - | $3.41 M(-26.5%) | $14.77 M(-2.3%) |
| Dec 2010 | $15.12 M(-0.5%) | $4.63 M(+37.4%) | $15.12 M(+3.6%) |
| Sept 2010 | - | $3.37 M(+0.5%) | $14.60 M(-2.2%) |
| June 2010 | - | $3.36 M(-10.6%) | $14.93 M(-3.5%) |
| Mar 2010 | - | $3.76 M(-8.6%) | $15.47 M(+1.8%) |
| Dec 2009 | $15.20 M(+3.9%) | $4.11 M(+11.0%) | $15.20 M(+6.5%) |
| Sept 2009 | - | $3.70 M(-5.1%) | $14.27 M(+1.8%) |
| June 2009 | - | $3.90 M(+12.0%) | $14.02 M(+0.4%) |
| Mar 2009 | - | $3.49 M(+9.7%) | $13.96 M(-4.6%) |
| Dec 2008 | $14.63 M(+31.2%) | $3.18 M(-7.9%) | $14.63 M(-5.0%) |
| Sept 2008 | - | $3.45 M(-10.3%) | $15.40 M(+4.1%) |
| June 2008 | - | $3.85 M(-7.5%) | $14.79 M(+11.0%) |
| Mar 2008 | - | $4.16 M(+5.3%) | $13.33 M(+19.5%) |
| Dec 2007 | $11.16 M(+61.4%) | $3.95 M(+39.0%) | $11.16 M(+16.4%) |
| Sept 2007 | - | $2.84 M(+19.3%) | $9.58 M(+17.6%) |
| June 2007 | - | $2.38 M(+20.0%) | $8.15 M(+10.6%) |
| Mar 2007 | - | $1.99 M(-16.4%) | $7.37 M(+6.6%) |
| Dec 2006 | $6.91 M(+102.3%) | $2.38 M(+69.2%) | $6.91 M(+20.4%) |
| Sept 2006 | - | $1.40 M(-12.5%) | $5.74 M(+16.1%) |
| June 2006 | - | $1.60 M(+4.7%) | $4.95 M(+19.5%) |
| Mar 2006 | - | $1.53 M(+27.3%) | $4.14 M(+21.2%) |
| Dec 2005 | $3.42 M(+32.9%) | $1.20 M(+97.7%) | $3.42 M(+12.3%) |
| Sept 2005 | - | $608.10 K(-23.7%) | $3.04 M(-1.8%) |
| June 2005 | - | $797.40 K(-1.4%) | $3.10 M(+8.0%) |
| Mar 2005 | - | $808.60 K(-2.2%) | $2.87 M(+11.6%) |
| Dec 2004 | $2.57 M(+5200.2%) | $827.20 K(+24.4%) | $2.57 M(+47.4%) |
| Sept 2004 | - | $664.90 K(+17.2%) | $1.74 M(+41.5%) |
| June 2004 | - | $567.50 K(+11.1%) | $1.23 M(+66.4%) |
| Mar 2004 | - | $511.00 K(+233.3%) | $740.10 K(+169.4%) |
| Sept 2003 | - | $153.30 K(+102.2%) | $274.70 K(+126.3%) |
| June 2003 | - | $75.80 K(+66.2%) | $121.40 K(+166.2%) |
| Mar 2003 | - | $45.60 K | $45.60 K |
| Dec 2001 | $48.50 K | - | - |
FAQ
- What is Halozyme Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual SG&A year-on-year change?
- What is Halozyme Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly SG&A year-on-year change?
- What is Halozyme Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Halozyme Therapeutics?
- What is Halozyme Therapeutics TTM SG&A year-on-year change?
What is Halozyme Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of HALO is $149.18 M
What is the all time high annual SG&A for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual selling, general & administrative expenses is $149.18 M
What is Halozyme Therapeutics annual SG&A year-on-year change?
Over the past year, HALO annual selling, general & administrative expenses has changed by +$5.66 M (+3.94%)
What is Halozyme Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of HALO is $41.24 M
What is the all time high quarterly SG&A for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly selling, general & administrative expenses is $57.48 M
What is Halozyme Therapeutics quarterly SG&A year-on-year change?
Over the past year, HALO quarterly selling, general & administrative expenses has changed by +$5.97 M (+16.93%)
What is Halozyme Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of HALO is $916.17 M
What is the all time high TTM SG&A for Halozyme Therapeutics?
Halozyme Therapeutics all-time high TTM selling, general & administrative expenses is $167.05 M
What is Halozyme Therapeutics TTM SG&A year-on-year change?
Over the past year, HALO TTM selling, general & administrative expenses has changed by +$766.85 M (+513.55%)